Contact Us
Drug Search Results
More Filters [+]

Lurbinectedin

Alternative Names: lurbinectedin, pm-01183, pm01183, pm 01183, zepzelca
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Lurbinectedin is a novel anticancer agent that inhibits transactivated transcription and modulates tumor microenvironment. Lurbinectedin showed high activity for patients with second-line SCLC when treated in combination with doxorubicin (Sourced from: https://www.iaslc.org/iaslc-news/press-release/lurbinectedin-does-not-improve-overall-survival-sclc-some-positive-action)

Mechanisms of Action: DNA Degrader

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: Accelerated Approval - Lung Cancer|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer *

Approval Status: Approved

Approved Countries: Australia | Canada | Ecuador | Greece | Israel | Korea | Singapore | Sweden | Switzerland | United Arab Emirates | United States

Approved Indications: Lung Cancer | Oncology Solid Tumor Unspecified | Small Cell Lung Cancer | Oncology Unspecified

Known Adverse Events: Labor Pain | Pain Unspecified | Anemia | Leukopenia | Lymphopenia | Thrombocytopenia | Neutropenia | Musculoskeletal Pain | Constipation | Diarrhea

Company: Jazz
Company Location: DUBLIN L2 4
Company CEO: Bruce C. Cozadd
Additonal Commercial Interests: PharmaMar

Clinical Description

Map of Global Clinical Trials for Lurbinectedin

Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Denmark, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Mexico, Poland, Romania, South Korea, Spain, Switzerland, Taiwan, Turkey, United Kingdom, United States

Active Clinical Trial Count: 26

Highest Development Phases

Phase 3: Leiomyosarcoma|Lung Cancer|Small Cell Lung Cancer

Phase 2: Desmoplastic Small Round Cell Tumor|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Oncology Solid Tumor Unspecified|Sarcoma, Ewing|Small Cell Sarcoma|Transitional Cell Carcinoma

Phase 1: Liver Cancer|Ovarian Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2015-003602-16

P2

Active, not recruiting

Oncology Solid Tumor Unspecified

2029-11-30

PM1183-C-010-22

P3

Unknown Status

Leiomyosarcoma

2029-04-30

LY01017/CT-CHN-302

P3

Recruiting

Small Cell Lung Cancer

2027-12-31

EMERGE 101

P2

Recruiting

Sarcoma, Ewing

2026-12-01

Recent News Events

Date

Type

Title

10/15/2024

News Article

 Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

09/09/2024

News Article

 Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

09/09/2024

News Article

 AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024

08/01/2024

News Article

 IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions